← Back to Search

Metoprolol for Vasovagal Syncope

Phase 4
Waitlist Available
Led By Robert S Sheldon, MD
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial will determine if metoprolol can prevent fainting in people with vasovagal syncope, aged 40 and up.

Eligible Conditions
  • Vasovagal Syncope

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The measure will be the proportion of patients having at least one syncope recurrence.
Secondary outcome measures
A is the number, duration, and severity of presyncopal spells (as measured with the Calgary Presyncope Scale)
A will be quality of life as measured by the EQ-5D and the ISQL.
A will be the frequency of syncopal spells.
+1 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: MetoprololActive Control1 Intervention
Metoprolol 50 mg po tablets will be provided for final dosing range (25 mg po BID to 100 mg po BID) for study duration (1 year). Patients will be started at 50 mg po BID and titrated over 2 weeks to target of 100 mg po BID.
Group II: PlaceboPlacebo Group1 Intervention
Matching placebo will be identical in appearance to the active treatment pill. Patients will be started at 50 mg po BID and titrated over 2 weeks to target of 100 mg po BID.

Find a Location

Who is running the clinical trial?

Vanderbilt UniversityOTHER
704 Previous Clinical Trials
6,143,337 Total Patients Enrolled
1 Trials studying Vasovagal Syncope
134 Patients Enrolled for Vasovagal Syncope
University of CalgaryLead Sponsor
792 Previous Clinical Trials
869,102 Total Patients Enrolled
4 Trials studying Vasovagal Syncope
332 Patients Enrolled for Vasovagal Syncope
Robert S Sheldon, MDPrincipal InvestigatorUniversity of Calgary

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
American Heart JournalJournal
Rationale for the Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Trial (POST5)
Raj, Satish R., Peter D. Faris, Lisa Semeniuk, Braden Manns, Andrew D. Krahn, Carlos A. Morillo, David G. Benditt, and Robert S. Sheldon. 2016. “Rationale for the Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Trial (POST5)”. American Heart Journal. Elsevier BV. doi:10.1016/j.ahj.2016.01.017.
clinicaltrials.govStudy
Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects
Dr. Bob Sheldon 2014. "Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02123056.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top